For low-risk patients, less radiation is as good, I would love to hear input from Rad Onc. I did notice that the Rad Oncs I work with are adopting this.
In the world of maintenance, Taxanes don’t add survival benefits.
Another maintenance trial, NO statistically significant OS benefit but prolonged time to second-line chemotherapy. HR was favored Olaparib.
Second line GIST, no difference in OS or PFS between sunitinib and ripretinib, but ripretinib is more tolerable.
Seems like maintenance month, I believe we are all practicing this, but confirmation of the benefit of maintenance PARP inhibitors in ovarian ca even in those without HRD.
This trial is an eye opener, I know many practice this, but this trial shows that treating women with confirmed thrombophilia and a history of miscarriages with anticoagulation during pregnancy DOES NOT IMPROVE OUTCOME OF LIVE BIRTHS compared to surveillance.
A small study but seems promising, for some patients surgery may not be needed after neoadjuvant therapy ( Triple negative and HER-2 neu positive). Colorectal surgeons in Orlando are avoiding surgery in some pts who respond to Neoadjuvant chemotherapy. Need more trials though.
Bispecific antibody, still with toxicity though, although pts had pretreatment with obinutumzumab to mitigate CRS. Response rate 35% in pts who received CAR-T therapy.
Two words: better and safer.
Another EGFR inhibitor beating chemotherapy in EGFR mutated NSCLC in the adjuvant setting.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
